Suggested remit - To appraise the clinical and cost effectiveness of pitolisant hydrochloride within its marketing authorisation for treating excessive daytime sleepiness caused by obstructive sleep apnoea
Status Proposed
Process STA 2018
ID number 1065

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
20 September 2018 - 18 October 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance